ATTO Stock — Attovia Therapeutics, Inc. Common Stock

Attovia Therapeutics, Inc. Common Stock (ATTO)

Updated October 16, 2026.

ATTO is a Stock. Total return is -37.3% over the past 0.2 years, 36.7 points behind SPY at -0.6%.

Attovia Therapeutics is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY platform technology. The company's pipeline includes candidates targeting chronic pruritic conditions, atopic dermatitis, and inflammatory bowel disease. As an early-stage biotech company, it does not currently distribute income to shareholders.

ATTO performance versus SPY

Price and return data through 2026-10-16.

Total return is -37.3% over the past 0.2 years, 36.7 points behind SPY at -0.6%.

ATTO key facts

Asset type

Stock

Asset class

Equity

Inception date

08/05/2026

Distribution frequency

None

Last close

$13.73 (as of 2026-10-16)

Market cap

$626,791,827

Average volume

977900.0

Payout ratio

0.0%

EPS

$-1.64

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ATTO risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider ATTO — and who may not

It is a weaker fit for investors who need monthly cash flow (ATTO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ATTO

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions